MAPT and Alzheimer disease: A clinical study showed that the exosome levels of total tau (pT181-tau and pS396-tau) were significantly higher in AD patients than in controls, suggesting that pS396-tau and pT181-tau levels in extracts of neutrally derived blood exosomes predict AD development before its clinical onset (Fiandaca et al., 2015).